Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
This is a brief. The reporting belongs to CNBC — read the complete story, with full context and credits, at the source.
Read the full story at CNBC ↗cnbc.com
More from the Business desk
Just in
Nvidia Is the Central Bank to AI’s Circular Economy. See Where the Money Goes.
Just in
Is Anthropic Worth $1.1 Trillion, or $1.5 Trillion? How to Make Sense of the Valuations
Just in
My wife pays thousands of dollars for her family to visit from Argentina. How can I convince her to stop?
Just in
